Abstract:Mutations in the gene encoding MFN2 have been identified as associated with Charcot–Marie–Tooth disease type 2A (CMT2A), a neurological disorder characterized by a broad clinical phenotype involving the entire nervous system. MFN2, a dynamin-like GTPase protein located on the outer mitochondrial membrane, is well-known for its involvement in mitochondrial fusion. Numerous studies have demonstrated its participation in a network crucial for various other mitochondrial functions, including mitophagy, axonal transport, and its controversial role in endoplasmic reticulum (ER)-mitochondria contacts. Considerable progress has been made in the last three decades in elucidating the disease pathogenesis, aided by the generation of animal and cellular models that have been instrumental in studying disease physiology. A review of the literature reveals that, up to now, no definitive pharmacological treatment for any CMT2A variant has been established; nonetheless, recent years have witnessed substantial progress. Many treatment approaches, especially concerning molecular therapy, such as histone deacetylase inhibitors, peptide therapy to increase mitochondrial fusion, the new therapeutic strategies based on MF1/MF2 balance, and SARM1 inhibitors, are currently in preclinical testing. The literature on gene silencing and gene replacement therapies is still limited, except for a recent study by Rizzo et al.( Rizzo et al., 2023 ), which recently first achieved encouraging results in in vitro and in vivo models of the disease. The near-future goal for these promising therapies is to progress to the stage of clinical translation.

Aminoacyl‐tRNA synthetases in Charcot–Marie–Tooth disease: A gain or a loss?

CMT disease severity correlates with mutation-induced open conformation of histidyl-tRNA synthetase, not aminoacylation loss, in patient cells

Aminoacyl‐tRNA synthetase defects in neurological diseases

Alternative stable conformation capable of protein misinteraction links tRNA synthetase to peripheral neuropathy.

A Novel Mutation of LRSAM1 in a Chinese Family with Charcot-Marie-Tooth Disease

Heterozygous <scp>Seryl‐tRNA</scp> synthetase 1 variants cause <scp>Charcot‐Marie‐Tooth</scp> disease

Drosophila Models for Charcot–Marie–Tooth Neuropathy Related to Aminoacyl-tRNA Synthetases

Charcot–Marie–Tooth disease-associated mutant tRNA synthetases linked to altered dimer interface and neurite distribution defect

CMT2N-causing aminoacylation domain mutants enable Nrp1 interaction with AlaRS

Aberrant GlyRS-HDAC6 Interaction Linked to Axonal Transport Deficits in Charcot-Marie-Tooth Neuropathy

Hearing impairment-associated KARS mutations lead to defects in aminoacylation of both cytoplasmic and mitochondrial tRNA Lys

Dominant aminoacyl-tRNA synthetase disorders: lessons learned from in vivo disease models

Impaired protein translation in Drosophila models for Charcot–Marie–Tooth neuropathy caused by mutant tRNA synthetases

CMT2D neuropathy is linked to the neomorphic binding activity of glycyl-tRNA synthetase

Charcot–Marie–Tooth mutation in glycyl-tRNA synthetase stalls ribosomes in a pre-accommodation state and activates integrated stress response

Neurodegeneration-related Aminoacy-Trna Synthetases

Current Treatment Methods for Charcot–Marie–Tooth Diseases

Alanyl-tRNA synthetase 1 (AARS1) gene mutation in a family with intermediate Charcot-Marie-Tooth neuropathy

Charcot-Marie-tooth disease type 2A: An update on pathogenesis and therapeutic perspectives

The role of tRNA synthetases in neurological and neuromuscular disorders

Transcriptional dysregulation by a nucleus-localized aminoacyl-tRNA synthetase associated with Charcot-Marie-Tooth neuropathy